Skip to main content

Table 4 Regional percent of Aβ deposition per year in a sample of subject with SCD (n = 168, dataset #3)

From: Early detection of amyloid load using 18F-florbetaben PET

  

Percent Aβ deposition per year

Method

Region

Aβ-negative

Gray zone

Established Aβ pathology

MRI-based ROIs

Frontal

− 0.01 ± 1.15 (p = 0.52)

1.08 ± 1.91 (p < 10−3)

2.72 ± 2.53 (p < 10−4)

Lateral temporal

0.08 ± 0.99 (p = 0.21)

1.07 ± 1.61 (p < 10−4)

2.05 ± 2.18 (p < 10−3)

Occipital

0.36 ± 1.13 (p < 10−3)

0.50 ± 1.74 (p = 0.38)

1.85 ± 2.18 (p < 10−3)

Parietal

0.12 ± 1.29 (p = 0.16)

1.39 ± 2.10 (p = 0.02)

2.61 ± 2.28 (p < 10−5)

Anterior cingulate

0.17 ± 1.81 (p = 0.13)

1.42 ± 2.12 (p = 0.10)

2.37 ± 3.07 (p = 0.001)

Posterior cingulate

0.71 ± 1.72 (p < 10−5)

N.A

3.14 ± 2.46 (p < 10−7)

Precuneus

0.31 ± 1.37 (p = 0.006)

N.A

N.A

Composite

0.24 ± 1.24 (p = 0.02)

1.66 ± 1.86 (p < 10−3)

2.40 ± 2.37 (p < 10−3)

CL

Cortex

0.00 ± 0.89 (p = 0.53)

1.81 ± 1.86 (p < 10−3)

2.38 ± 1.82 (p < 10−4)

  1. SCD subjective cognitive decline, N.A not available (As Aβ-negative, gray zone, and established Aβ pathology were defined regionally using cutoffs reported in Tables 2 and 3, there were not enough regional standardized uptake values (SUVRs) to calculate percent Aβ deposition per year in some regions), Aβ amyloid-beta, MRI magnetic resonance imaging, ROI region of interest, CL centiloid. p-values testing whether percent Aβ deposition per year is significantly larger than zero are given in parenthesis
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193